First Time Loading...

Neuropace Inc
NASDAQ:NPCE

Watchlist Manager
Neuropace Inc Logo
Neuropace Inc
NASDAQ:NPCE
Watchlist
Price: 13.56 USD -3.21% Market Closed
Updated: Apr 25, 2024

Intrinsic Value

NPCE's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

NeuroPace, Inc. develops, manufactures and markets implantable devices for treating epilepsy and neurological disorders. [ Read More ]

The intrinsic value of one NPCE stock under the Base Case scenario is 8.34 USD. Compared to the current market price of 13.56 USD, Neuropace Inc is Overvalued by 39%.

Key Points:
NPCE Intrinsic Value
Base Case
8.34 USD
Overvaluation 39%
Intrinsic Value
Price
Base Case Scenario

Valuation Backtest
Neuropace Inc

Backtest Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling NPCE stocks based on their intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Settings
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?

Fundamental Analysis

Beta
Ask me anything about
Neuropace Inc

Provide an overview of the primary business activities
of Neuropace Inc.

What unique competitive advantages
does Neuropace Inc hold over its rivals?

What risks and challenges
does Neuropace Inc face in the near future?

Has there been any significant insider trading activity
in Neuropace Inc recently?

Summarize the latest earnings call
of Neuropace Inc.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Neuropace Inc.

Provide P/S
for Neuropace Inc.

Provide P/E
for Neuropace Inc.

Provide P/OCF
for Neuropace Inc.

Provide P/FCFE
for Neuropace Inc.

Provide P/B
for Neuropace Inc.

Provide EV/S
for Neuropace Inc.

Provide EV/GP
for Neuropace Inc.

Provide EV/EBITDA
for Neuropace Inc.

Provide EV/EBIT
for Neuropace Inc.

Provide EV/OCF
for Neuropace Inc.

Provide EV/FCFF
for Neuropace Inc.

Provide EV/IC
for Neuropace Inc.

Show me price targets
for Neuropace Inc made by professional analysts.

What are the Revenue projections
for Neuropace Inc?

How accurate were the past Revenue estimates
for Neuropace Inc?

What are the Net Income projections
for Neuropace Inc?

How accurate were the past Net Income estimates
for Neuropace Inc?

What are the EPS projections
for Neuropace Inc?

How accurate were the past EPS estimates
for Neuropace Inc?

What are the EBIT projections
for Neuropace Inc?

How accurate were the past EBIT estimates
for Neuropace Inc?

Compare the revenue forecasts
for Neuropace Inc with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Neuropace Inc and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Neuropace Inc against its competitors.

Analyze the profit margins
(gross, operating, and net) of Neuropace Inc compared to its peers.

Compare the P/E ratios
of Neuropace Inc against its peers.

Discuss the investment returns and shareholder value creation
comparing Neuropace Inc with its peers.

Analyze the financial leverage
of Neuropace Inc compared to its main competitors.

Show all profitability ratios
for Neuropace Inc.

Provide ROE
for Neuropace Inc.

Provide ROA
for Neuropace Inc.

Provide ROIC
for Neuropace Inc.

Provide ROCE
for Neuropace Inc.

Provide Gross Margin
for Neuropace Inc.

Provide Operating Margin
for Neuropace Inc.

Provide Net Margin
for Neuropace Inc.

Provide FCF Margin
for Neuropace Inc.

Show all solvency ratios
for Neuropace Inc.

Provide D/E Ratio
for Neuropace Inc.

Provide D/A Ratio
for Neuropace Inc.

Provide Interest Coverage Ratio
for Neuropace Inc.

Provide Altman Z-Score Ratio
for Neuropace Inc.

Provide Quick Ratio
for Neuropace Inc.

Provide Current Ratio
for Neuropace Inc.

Provide Cash Ratio
for Neuropace Inc.

What is the historical Revenue growth
over the last 5 years for Neuropace Inc?

What is the historical Net Income growth
over the last 5 years for Neuropace Inc?

What is the current Free Cash Flow
of Neuropace Inc?

Discuss the annual earnings per share (EPS)
trend over the past five years for Neuropace Inc.

Financials

Balance Sheet Decomposition
Neuropace Inc

Current Assets 92.7m
Cash & Short-Term Investments 66.5m
Receivables 12.3m
Other Current Assets 14m
Non-Current Assets 14.9m
PP&E 14.4m
Other Non-Current Assets 524k
Current Liabilities 16.2m
Accounts Payable 2.3m
Accrued Liabilities 12.8m
Other Current Liabilities 1.1m
Non-Current Liabilities 70.8m
Long-Term Debt 57m
Other Non-Current Liabilities 13.8m
Efficiency

Earnings Waterfall
Neuropace Inc

Revenue
65.4m USD
Cost of Revenue
-17.3m USD
Gross Profit
48.1m USD
Operating Expenses
-75.3m USD
Operating Income
-27.2m USD
Other Expenses
-5.8m USD
Net Income
-33m USD

Free Cash Flow Analysis
Neuropace Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
History
Components
Chart
Table
Fundamental Scores

NPCE Profitability Score
Profitability Due Diligence

Neuropace Inc's profitability score is 26/100. The higher the profitability score, the more profitable the company is.

Positive Gross Profit
Positive Revenue Growth Forecast
Exceptional 1-Year Revenue Growth
Negative Operating Income
26/100
Profitability
Score

Neuropace Inc's profitability score is 26/100. The higher the profitability score, the more profitable the company is.

NPCE Solvency Score
Solvency Due Diligence

Neuropace Inc's solvency score is 33/100. The higher the solvency score, the more solvent the company is.

Short-Term Solvency
Negative Net Debt
Long-Term Solvency
High D/E
33/100
Solvency
Score

Neuropace Inc's solvency score is 33/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

NPCE Price Targets Summary
Neuropace Inc

Wall Street analysts forecast NPCE stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for NPCE is 18.19 USD with a low forecast of 13.13 USD and a high forecast of 21 USD.

Lowest
Price Target
13.13 USD
3% Downside
Average
Price Target
18.19 USD
34% Upside
Highest
Price Target
21 USD
55% Upside
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Ownership

NPCE Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Shareholder Return

NPCE Price
Neuropace Inc

1M 1M
+4%
6M 6M
+112%
1Y 1Y
+205%
3Y 3Y
-48%
5Y 5Y
-46%
10Y 10Y
-46%
Annual Price Range
13.56
52w Low
3.98
52w High
17.5
Price Metrics
Average Annual Return -72.22%
Standard Deviation of Annual Returns 19.75%
Max Drawdown -95%
Shares Statistics
Market Capitalization 377.3m USD
Shares Outstanding 28 344 600
Percentage of Shares Shorted 0.65%

NPCE Return Decomposition
Main factors of price return

What is price return decomposition?

Company Profile

Neuropace Inc Logo
Neuropace Inc

Country

United States of America

Industry

Health Care

Market Cap

377.3m USD

Dividend Yield

0%

Description

NeuroPace, Inc. develops, manufactures and markets implantable devices for treating epilepsy and neurological disorders. The company is headquartered in Mountain View, California. The company went IPO on 2021-04-22. The firm is focused on transforming the lives of people suffering from epilepsy by reducing or eliminating the occurrence of debilitating seizures. The Company’s novel and differentiated RNS System is the brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source. The Company’s RNS System is a platform that delivers care for patients suffering from drug-resistant epilepsy and offers a personalized solution and outcomes to the patients suffering from other brain disorders. RNS System is a device that records brain activity data and clinicians to monitor patients. RNS System monitors the brain’s electrical activity, recognizes patient-specific abnormal patterns, and delivers treatment at the seizure source. The Company’s RNS System is engaged in treating other brain disorders including depression, impulse control disorders, memory disorders, and post-traumatic stress.

Contact

CALIFORNIA
Mountain View
455 N. Bernardo Avenue
+16502372700.0
https://www.neuropace.com/

IPO

2021-04-22

Employees

152

Officers

Chief Medical Officer
Dr. Martha J. Morrell
CEO, President & Director
Mr. Joel D. Becker
CFO, VP of Finance & Administration and Assistant Secretary
Ms. Rebecca L. Kuhn
Vice President of Sales
Ms. Kelley Nicholas
Vice President of Human Resources
Ms. Irene Thomas

See Also

Discover More
What is the Intrinsic Value of one NPCE stock?

The intrinsic value of one NPCE stock under the Base Case scenario is 8.34 USD.

Is NPCE stock undervalued or overvalued?

Compared to the current market price of 13.56 USD, Neuropace Inc is Overvalued by 39%.